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Background: Ghrelin is a natural ligand of the growth hormone secretagogue receptor (GHS-R). They are often
co-expressed in multiple human tumors and related cancer cell lines what can indicate that the ghrelin/GHS-R axis
may have an important role in tumor growth and progression. However, a role of ghrelin in canine tumors remains
unknown. Thus, the aim of our study was two-fold: (1) to assess expression of ghrelin and its receptor in canine
mammary cancer and (2) to examine the effect of ghrelin on carcinoma cells proliferation, apoptosis, migration and
invasion. The expression of ghrelin and its receptor in canine mammary cancer tissues and cell lines (isolated
from primary tumors and their metastases) was examined using Real-time qPCR and immunohistochemistry.
For apoptosis analysis the Annexin V and propidium iodide dual staining was applied whereas cell
proliferation was evaluated by MTT assay and BrdU incorporation test. The influence of ghrelin on cancer cells
migration and invasion was assessed using Boyden chamber assays and wound healing assay.
Results: The highest expression of ghrelin was observed in metastatic cancers whereas the lowest expression
of ghrelin receptor was detected in tumors of the 3rd grade of malignancy. Higher expression of ghrelin and
its receptor was detected in cancer cell lines isolated from metastases than in cell lines isolated from primary
tumors. In vitro experiments demonstrated that exposure to low doses of ghrelin stimulates cellular
proliferation, inhibits apoptosis and promotes motility and invasion of canine mammary cancer cells. Growth
hormone secretagogue receptor inhibitor ([D-Lys3]-GHRP6) as well as RNA interference enhances early
apoptosis.
Conclusion: The presence of ghrelin and GHS-R in all of the examined canine mammary tumors may indicate
their biological role in cancer growth and development. Our experiments conducted in vitro confirmed that
ghrelin promotes cancer development and metastasis.
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Ghrelin was identified in human and rat stomach in 1999
by Kojima et al. [1] as endogenous ligand for growth
hormone secretagogue receptor type 1a (GHS-R1a). It
belongs to the G protein coupled receptor family and
is widely distributed along various tissues. GHS-R has
two variants of splicing: functional type 1a and truncated* Correspondence: magdalena_krol@sggw.pl
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reproduction in any medium, provided the ortype 1b, which arises from an alternative splicing and its
function is still unclear [2,3].
The GHS-R activation in pituitary results in consider-
ably increased secretion of growth hormone (GH). This
is the main effect of ghrelin activity in humans and in
animals. Ghrelin is a highly conserved peptide among
various species [1,4]. It is mainly produced by endocrine
X/A-like cells of stomach’s submucosal layer and, secreted
directly into the blood [5]. However, the presence of ghre-
lin has also been detected in other areas of gastrointestinal
tract, as well as in many other tissues [6].
In healthy dogs, ghrelin regulates feeding behavior and
energy metabolism. Plasma ghrelin levels increase beforeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are associated with the insulin and glucose concentration
[7,8]. Some studies on dogs suggested role of ghrelin in
the development of adipositas due to higher circulating
levels of ghrelin in obese dog than in normal or lean ani-
mals [7,9].
The ghrelin expression (and its receptor) has also been
observed in multiple endocrine and non-endocrine tu-
mors and related cell lines in humans, such as: pituitary
adenomas, thyroid follicular cancer and parathyroid ad-
enomas, pancreatic-related endocrine tumors, oral squa-
mous cell carcinoma, gastric carcinoids, colon cancer,
renal carcinoma, bronchial carcinoid, testicular and ovar-
ian tumors, adrenocortical tumors, prostate cancer and
breast cancer [10]. The co-expression of ghrelin and its
receptor in various tumors and cancer cell lines may in-
dicate their autocrine/paracrine role in the tumor growth
and development. Thus, the effect of ghrelin on cancer
cells was investigated in multiple in vitro experiments in
humans and rats, however the result are contradictory
[11-22].
The role of ghrelin/GHS-R axis in tumor initiation,
progression and metastasis in animals is still unclear. As
far as we realize, there are no published studies about the
expression and function of ghrelin in canine tumors. Our
previous studies have shown that cell lines with the high-
est proliferative potential have high expression of GHS-R
[23]. Moreover, we found its up-regulation in metastatic
cancer cell lines (isolated from canine mammary cancer
metastases to the lungs) what may indicate the role of
ghrelin and GHS-R in metastasis [24]. This study was
therefore designed to characterize the expression of ghre-
lin and its receptor in canine mammary cancer tissues
and cancer cell lines. We have also examined the effect




The cell lines used for this study have previously been
given an account of Król et al. [23-25]. Two adenocarcin-
oma cell lines isolated from the canine mammary gland
tumors (CMT-W1 and CMT-W2) and two cell lines
isolated from their lung metastases (CMT-W1M and
CMT-W2M) were kindly donated by Prof. Dr. Maciej
Ugorski and Dr. Joanna Polanska from Wroclaw Univer-
sity (Poland). The cell lines were cultivated in RPMI-
1640 medium containing 10% heat-inactivated fetal
bovine serum (FBS), 50 U/ml penicillin, 50 μg/ml strepto-
mycin, 2,5 μg/ml amphotericin B (reagents obtained from
Sigma Aldrich Chemical Co., USA) and grown in tissue
culture flasks (Nunc™, Denmark) in an atmosphere of
5% CO2 and 95% humidified air at 37°C, and routinely
subcultured every second day.Tissue samples
Canine mammary tumor tissue sections were derived
from the archives of the Department of Pathology and
Veterinary Diagnostics, Faculty of Veterinary Medicine,
Warsaw University of Life Sciences –WULS (Poland).
The samples were surgically obtained during the mastec-
tomy from 50 female dogs of various breeds. The tissue
samples were fixed in 8% neutral buffered formalin and
routinely embedded in paraffin. Eighteen canine mam-
mary tumors were snap frozen using liquid nitrogen and
archived at -80°C.
Most of the cases’ information about the presence/
absence of metastases was known. The tumors that gave
metastases were surgically removed together with the
metastatic site. The presence of neoplastic cells on the
metastatic site was histologically confirmed. The immu-
nohistochemical examination of cytokeratin, vimentin,
smooth muscle actin, s100 protein and p63 protein ex-
pression was performed (data not shown). Histological
diagnoses were achieved on haematoxylin and eosin (HE)
stained slides according to the World Health Organiza-
tion (WHO) Histological Classification and Mammary
Tumors of the Dog and Cat classification [26]. Tumor
grading was based on the Misdorp [27] classification and
was evaluated in respect to tubule formation, degree of
differentiation and mitotic index as: the 1st, the 2nd and
the 3rd grade of malignancy. The tumors were classified
as benign adenomas or malignant carcinomas (simple car-
cinomas or complex carcinoma). The tumors were divided
into five categories: benign adenomas (n = 10), malignant
adenocarcinomas: of the 1st grade of malignancy (n = 10),
of the 2nd grade of malignancy (n = 10), of the 3rd grade
of malignancy (n= 10) and metastatic (n= 10) (which gave
local or distant metastases).
Immunohistochemistry (IHC)
Four micrometer (4 μm) sections from paraffin blocks
containing tumor tissue were baked in 37°C overnight.
After dewaxing in xylene and rehydration in ethanol, for
antigen retrieval, the slides were placed in 0.02 M citrate
buffer, pH 6.0 and boiled in the decloaking chamber.
The cell lines were cultured on Lab-Tek (Nunc Inc.
USA) 4-chamber culture slides for 24 hrs and subjected
to the immunohistochemical analysis after ethanol (70%)
fixation (10 min).
The samples were incubated in the Peroxidase Block-
ing Reagent (Dako, Denmark) for 10 min at room tem-
perature prior to the antibody incubation. After 30 min
incubation in 5% bovine serum albumin (Sigma Aldrich,
Germany), the following primary antibodies were used
(diluted in 1% bovine serum): rabbit polyclonal anti-
ghrelin (Abcam, United Kingdom) diluted 1:50 and incu-
bated one hour at room temperature; rabbit polyclonal
anti-Growth Hormone Secretagogue Receptor (Novus
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at +4°C. For the staining the EnVision kit (Labelled Poly-
mers consist of secondary anti-rabbit antibodies con-
jugated with the HRP enzyme complex obtained from
Dako) was used. To develop a colored product, the 3,30-
Diaminobenzidine (DAB) substrate was used (Dako). Fi-
nally, the hematoxyline was used for nuclei counterstaining.
For each immunohistochemical experiment of paraffin
slides, positive controls were set aside: canine stomach
(for ghrelin) and canine pituitary (for GHS-R). For each
experiment of paraffin slides and cell lines the negative
control was stained without use of primary antibodies.
Three consecutive tissue sections and four slides of
each cell line were analyzed. Ten to 20 pictures of each
slide were taken (depending on the sample size) using
Olympus microscopy BX60. Only the regions of cancer
cells and stroma were analyzed in the primary tumors
whereas the necrotic regions were avoided. The number
of ghrelin positive cells (brown color) and the colorimet-
ric intensity of the GHS-R expression reflected as IHC-
stained antigen spots (brown color) were counted by a
computer-assisted image analyzer (Olympus Microimage™
Image Analysis, software version 4.0 for Windows, USA).
The antigen spot color intensity is expressed as a mean
pixel integrated optical density (IOD) on a 1-40,000 scale.
Real-time qPCR
Total RNA from the frozen canine mammary tissues
and cell lines suspensions was isolated using a Total
RNA kit (A&A Biotechnology, Poland) according to the
manufacturer’s protocol. Isolated RNA samples were dis-
solved in RNase-free water. The quantity of isolated RNA
was measured using NanoDrop (NanoDrop Technologies,
USA). The samples with adequate amounts of RNA were
treated with DNaseI to eliminate DNA contamination.
The samples were subsequently purified using RNeasy
MiniElute Cleanup Kit (Qiagen). Finally RNA samples
were analyzed on a BioAnalyzer (Agilent, California, USA)
to measure final RNA quality and integrity.
The ghsr and ghrl primers were designed using PRI-
MER3 software (free on-line access) and checked using
Oligo Calculator (free on-line access) and Primer-Blast
(NCBI database). The used sequences for ghsr were as
follow: 1) TTCCACGTGGGCGATATTTATT and TGG
CAGCACTGAGGTAGAAGAGG (to assess ghsr expres-
sion at mRNA level in examined cell lines and tissues)
and CCTGGTATCCTTTGTCCTCTTCT and CTTTC
ATCCTTCAGAGTGGAGAG (to assess ghsr knockdown
effect after siRNA treatment). The optimal annealing
time for the first pair was 5 sec, whereas optimal anneal-
ing temperature was 59°C. The optimal annealing time
for the second pair was 10 sec, whereas optimal anneal-
ing temperature was 63°C. The used sequences for ghrl
were as follow: TCAGGTGAGTGCTTCTAGGG andCACTCGGGAAGTTTCTTCAA. The optimal annealing
time was 5 sec, whereas optimal temperature was 61°C.
rps19 and hprt genes were used as a non-regulated re-
ference for the normalization of target gene expression
(sequences and reaction conditions has been previously
given an account of: [23-25,28,29].
Quantitative RT-PCR was performed using fluoro-
genic SYBR Green and the Sequence Detection System,
Fast 7500 (Applied Biosystems). Data analysis was car-
ried out using the 7500 Fast System SDS Software Ver-
sion 1.4.0.25 (Applied Biosystems, USA). The results
were analyzed using comparative Ct method [30]. Rela-
tive transcript abundance of the gene equals ΔCt values
(ΔCt =Ctreference – Cttarget). Relative changes in tran-
script are expressed as ΔΔCt values (ΔΔCt =ΔCtcontrol –
ΔCtexamined). The experiment was conducted three times.
Cell viability assay (MTT-assay)
Cell viability (metabolic activity of viable cells) was quan-
tified by MTT assay. Cells were seeded into 96-well plate
(Nunc Inc., Denmark) at the concentration of 6 × 104
cells per well. When cells reached 60-70% confluence,
the medium was replaced with medium containing 10%
FBS and n-octanoylated ghrelin peptide (Peptides Inter-
national) at the concentrations of 1, 10, 100 and 1000
nM. To protect ghrelin from inactivation, the culture
medium contained also 20 nM serine protease inhibitor,
4-(2-aminoethyl) benzenesulphonyl fluoride hydrochlor-
ide (AEBSF, Sigma Aldrich) [31]. The cultures were incu-
bated for 24 hours.
In order to determine the mechanism by which ghrelin
increased proliferation/viability of the cells (to assess if it
acts via GHS-R), they were additionally pre-treated for
1 hr with the 100 and 200 μM of GHS-R-specific antag-
onist [D-Lys3]-GHRP6 (Peptides International). Then,
cells were incubated in 0.5 mg/ml tetrazolium salt MTT
diluted in phenol red-free RPMI 1640 medium (Sigma
Aldrich) for 4 hrs at 37°C. To complete solubilization of
the formazan crystals, 100 μl of DMSO (Dimethyl sulfox-
ide, Sigma Aldrich) was added to each well. Cells viability
was quantified by measuring photometric absorbance
at 570 nm in multi well plate reader Infinite 200 PRO
Tecan™ (TECAN, Mannedorf, Switzerland). All the sam-
ples were examined in triplicate, each experiment was
conducted five times (n = 15).
Cell proliferation assay (BrdU incorporation assay)
BrdU cell proliferation assay was carried out according
to the BrdU labeling protocol (BD Bioscience, USA).
Briefly, canine mammary cancer cells where cultivated in
culture flask to reach 60-70% confluence. The medium
was then removed and replaced medium containing 10%
FBS with 20 nM AEBSF and: (1) ghrelin at the concen-
tration of 1, 10, 100 and 1000 nM or (2) GHS-R-specific
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and 1000 μM) for 24 hrs. Then, 10 μM of BrdU (BD Bio-
science) was added to culture medium for one hour. The
cells were washed twice with PBS, harvested by trypsini-
zation, suspended in PBS and fixed in ice-cold ethanol
(70%). The cells were then stored at -20°C for 12 hrs
and then washed with Wash Buffer (BD Bioscience,
USA) and suspended in denaturing solution (2M HCl)
for 20 min at room temperature (RT) to denature DNA.
The cells were then washed again with Wash Buffer and
resuspended in 0.1 M sodium borate (Na2B4O7, Sigma
Aldrich, USA) of pH 8.5, for 2 minutes at RT, to neu-
tralize any residual acid. The cells were then washed
with Wash Buffer and incubated with FITC-conjugated
anti-BrdU antibodies (20 μl) and isotype control (BD
Bioscience, USA) for 30 min at RT. Cells were then in-
cubated with 10 μl/ml of propidium iodide (PI) (Sigma
Aldrich) for 30 min at RT. All the samples were analyzed
using flow cytometry (FACS Aria II, Becton Dickinson,
USA). The experiment was conducted in three replicates.
siRNA transfection
The siRNA transfection procedure on canine mammary
cancer cells has been given an account of in our previ-
ous paper [25]. However, the procedure was optimized
for CMT-W1M cell line. Thus the cell density, transfec-
tion reagent toxicity and transfection efficacy has been
assessed (according to the procedure described in our
previous manuscript: [25]). The canine (Canis lupus
familiaris) ghsr sequence was obtained from Gene Bank
with accession number [EF536345.1]. The siRNA dup-
lexes were designed by http://www.sigmaaldrich.com/
life-science/custom-oligos/sirna-oligos/sirna-design-service.
html. The results were confirmed using two independent
algorithms: Dharmacon (OligoWalk) and Ambion and at
last two duplexes were chosen for further experiments
(obtained from Sigma Aldrich) (1st duplex sequences,
ghr1, are as follow: CCAUCAAUCCCAUUCUGUAdTdT
and UACAGAAUGGGAUUGAUGGdTdT; 2nd duplex
sequences, ghr2, are as follow: GCUCUCCACUCUGA-
AGGAUdTdT and AUCCUUCAGAGUGGAGAGCdTdT).
Each duplex was used at 2 different concentrations
(ghr1 or ghr2, and ghr10 or ghr20 at concentration of 6
or 12 pmol, respectively) the mixture of both duplexes
was also used (ghr1 + ghr2: 6 pmol + 6 pmol). The RNA
interference has been assessed by Real-time qPCR.
Transfected and control CMT-W1M cells (cells cultured
according to the transfection procedure with transfec-
tion reagent + non-coding RNA (Negative Universal Con-
trol, Invitrogen)) were scraped, and the total RNA from
the cell suspension samples was isolated. Because during
optimization of the siRNA transfection procedure for
CMT-W1M cell line any significant changes in cells via-
bility between control cells and cells treated with onlytransfection reagent has been observed (data not shown),
the mock-transfected control has been omitted.Apoptosis assay
The Annexin V-FITC and propidium iodide (PI) dual
staining was applied for apoptosis analysis. Normal cells
and cells treated with (1) ghrelin at the concentration of
1, 10, 100 and 1000 nM and 20 nM AEBSF, (2) inhibitor
of ghrelin receptor [D-Lys3]-GHRP6 at the concentra-
tion of 10 μM, 100 μM, 200 μM, 500 μM and 1000 μM
for 24 hrs (3) transfection reagent + non-coding RNA (as
a control for transfected cells) and (4) ghsr siRNA, were
harvested by trypsinization and together with the cells
floated in medium were stained using an Annexin V Kit
(Becton Dickinson, USA), according to the manufac-
turer’s protocol. The cells were immediately (within
1 hr) analyzed by flow cytometry (BD FACS Aria II,
Becton Dickinson, USA). Early apoptotic cells with
exposed phosphatidylserine but intact cell membranes
bound to Annexin V-FITC but excluded PI. Cells in late
apoptotic stages were labeled with both Annexin V-
FITC and PI, whereas necrotic cells were labeled with PI
only. All samples were assayed in triplicate, and each ex-
periment was performed three times (n = 9).In vitro wound healing assay (scratching test)
Scratch assay was conducted to assess the influence of
ghrelin on canine mammary carcinoma cell motility.
The cells were seeded in a high density at 600 mm Petri
dishes (Corning-Costar, Cambridge, MA, USA). After
24 hrs, the medium was removed and replaced medium
containing 10% FBS with 20 nM AEBSF and (1) ghrelin
at concentration of 1, 10, 100 and 1000 nM or (2) spe-
cific GHS-R inhibitor [D-Lys3]-GHRP6 at concentration
of 10 uM, 100 μM, 200 uM, 500 μM and 1000 μM for
24 hrs. When the cells reached full confluence, the mono-
layers were wounded by scratching the surface as uni-
formly and straight as possible with a pipette tip (1000 μl)
at least three times. The images of cells invading the
scratch were captured at indicated time points (0, 3, 6,
9, 12 and 24 hrs) using phase contrast microscopy (IX
70 Olympus Optical Co., Germany). The pictures have
been analyzed using a computer-assisted image analyzer
(Olympus Microimage™ Image Analysis, software ver-
sion 4.0 for Windows, USA). The migration rate was ex-
pressed as percentage of scratch closure and was
calculated as follows: % of scratch closure = a-b/a, where
(a) is a distance between edges of the wound, and (b) is
the distance which remained cell-free during cell migra-
tion to close the wound [32]. The values are the means of
three independent wound fields from three independent
experiments (n = 9).
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The BD BioCoat™ 24-Multiwell Invasion System (BD
Biosciences, USA) pre-coated with BD Matrigel™ Matrix
were used according to the manufacturer’s protocol. The
insert plates were prepared by rehydrating the BD Matri-
gel™ Matrix layer with phosphate buffered saline (PBS)
for two hours at 37°C. The rehydration solution was then
carefully removed, and 500 μl of cell suspension was
added to the apical chambers (2.5 × 105 cells). Cell sus-
pension was prepared by trypsinizing cell monolayers
(80% confluent) and resuspending the cells in RPMI
1640 medium containing 0.1% FBS, 20 nM of AEBSF and
ghrelin at the concentration of 1, 10 and 100 nM. Then
750 μl of chemoattractant (10% FBS) was added to the
each of the basal chambers. Assay plates were incubated
for 22 hours at standard culturing conditions. Followed
incubation medium was carefully removed from apical
chamber and insert system was transferred into a second
24-well plate containing 500 μl of 2.5 μg/ml Calcein AM
in Hanks’ Balanced Salt solution (HBSS). Plates were
incubated one hour at standard culturing conditions.
Then the fluorescence of invaded cells was measured at
excitation wavelength 485 nm and emission wavelength
530 nm using florescent plate reader with bottom read-
ing capabilities Infinite 200 PRO Tecan™ (TECAN,
Switzerland). All samples were assayed in triplicate, and
each experiment was conducted three times (n = 9).
To evaluate migratory potential the BD Falcon™
FluoroBlock™ 24-Multiwell Insert Plates (8 micron pore
size) (BD Biosciences, USA) was used. The determination
protocol for the canine mammary cancer cells migration
was the same as the invasion assay, with the exception
that no Matrigel was used and rehydrating of the plate
was omitted. In order to determine fluorescence of
cells invaded through membrane coated by MatrigelFigure 1 Ghrelin and growth hormone secretagogue receptor expres
relative gene expression level (ratio) of (A) ghrelin and (B) growth hormon
3rd grade of malignancy (total n = 18) determined using Real-time PCR. The
The statistical analysis was performed using Prism version 5.00 software (Gr
test were applied. p < 0.05 was regarded as significant and marked as *.fluorescence microscopic analysis using Olympus mi-
croscopy BX60 at x4 magnifications was applied.
Statistical analysis
The statistical analysis was conducted using Prism ver-
sion 5.00 software (GraphPad Software, California, USA).
The one-way ANOVA and Tukey HSD (Honestly Signifi-
cant Difference) post-hoc test, Dunnett’s test and t-test
were applied as well as regression analysis. The p-value
< 0.05 was regarded as significant whereas p-value < 0.01
and p-value < 0.001 as highly significant. The data was
expressed as means +/- S.E.M. unless otherwise stated.
The in vitro wound healing assay was analyzed using
two-way RM ANOVA and Bonferroni post-hoc test.
Results
Expression of ghrelin and GHS-R in canine mammary
tumors and in canine mammary carcinoma cell lines
The expression of ghrelin and growth hormone se-
cretagogue receptor at mRNA level was detected in ad-
enocarcinomas of the 1st, the 2nd and the 3rd grade of
malignancy (total n = 18). No significant differences in
ghrelin mRNA level have been observed between these
groups (Figure 1A), however mRNA level of growth hor-
mone secretagogue receptor was significantly lower
(p < 0.05) in tumors of the 3rd grade of malignancy com-
pared to the tumors of the 2nd grade of malignancy
(Figure 1B).
The expression of ghrelin peptide was detected in
both benign and malignant canine mammary tumors.
The analysis showed that ghrelin immunoreactivity was
significantly lower (p < 0.05) in benign tumors (aden-
omas) comparing to the tumors that gave local or dis-
tant metastases (carcinomas) (1571 ± 183.5 and 2612 ±
345.9, respectively) (Figure 2A, B). The number of ghrelin-sion at mRNA level in canine mammary adenocarcinomas. The
e secretagogue receptor in adenocarcinomas of the 1st, the 2nd, the
result are presented as a mean (±SEM) from 6 tumors in each group.
aphPad Software, USA). The one-way ANOVA and Tukey HSD post-hoc
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tumors from benign to the most malignant samples, how-
ever no significant differences between these groups have
been observed (Figure 2A, B).
Immunohistochemistry also demonstrated expression
of growth hormone secretagogue receptor (GHS-R) in
all benign and malignant canine mammary tumors. Sig-
nificantly lower expression (p < 0.01) of this antigen was
found in tumors of the 3rd grade of malignancy (1500 ±
182.6) than in tumors of the 2nd grade of malignancy or
in metastatic tumors (3204 ± 377.6 and 2990 ± 335.9, re-
spectively) (Figure 3A, B). No significant differences have
been observed between the other tumor groups.
Real-time PCR analysis showed ghrelin and growth
hormone secretagogue receptor mRNA expression in all
the examined cell lines (Figure 4A, B). Growth hormone
secretagogue receptor expression was significantly higher
in the cell lines isolated from mammary carcinoma me-
tastases to the lungs (see also our previous paper: [23]).
Immunohistochemical examination confirmed expres-
sion of both peptides in all of the examined cell lines
(Figures 5, 6). Significantly lower expression (p < 0.01) of
ghrelin antigen was detected in cell line isolated fromFigure 2 Ghrelin expression in canine mammary tumors. (A) Light mic
the 2nd, the 3rd grade of malignancy and tumors that gave local/distal met
magnification of x20). The ghrelin antigen is represented by brown colored
(IOD) of ghrelin-positive cells in canine mammary tumors. The colorimetric
computer-assisted image analyzer (Olympus Microimage™ Image Analysis,
slide were analyzed. The result are presented as a mean (±SEM) from 10 tu
version 5.00 software (GraphPad Software, USA). The one-way ANOVA and
regarded as significant and marked as *.primary canine mammary adenocarcinoma (CMT-W1)
than in the cell line isolated from its metastasis to the
lungs (CMT-W1M) (5030 ± 428.4 and 7494 ± 548.3, re-
spectively). The immunoreactivity of ghrelin was simi-
lar in another pair of the cell lines (7764 ± 778.5 and
7537 ± 773.1 in CMT-W2 and CMT-W2M, respectively)
(Figure 5A, B). However, GHS-R immunoreactivity was
significantly lower (p < 0.05) in both canine mammary
carcinomas isolated from primary tumors than in cell
lines isolated from their metastases to the lungs: 5230 ±
399.5 and 6729 ± 462.7 in CMT-W1 and CMT-W1M
cell lines, respectively and 6189 ± 433.0 and 7792 ± 401.9
in CMT-W2 and CMT-W2M cell lines, respectively
(Figure 6A, B).
Ghrelin enhances viability and proliferation of canine
mammary cancer cells
Ghrelin treatment increased cells viability (determined
by MTT assay) and cells proliferation (assessed using
BrdU incorporation assay) in three of the examined cell
lines except the CMT-W2M cell line. The viability of the
CMT-W1 cells was significantly increased by approxi-
mately 14% when treated with 1 nM n-octanoylatedrographs of canine mammary adenomas, adenocarcinomas of the 1st,
astases (total n = 50) obtained with Olympus BX60 microscope (at the
precipitate in cytoplasm. (B) The graph of integrated optical density
intensity of the IHC-stained antigen spots was evaluated by a
software version 5.0 for windows, USA). Ten to 20 pictures in each
mors in each group. The statistical analysis was performed using Prism
Tukey HSD post-hoc were applied to analyze the results. p < 0.05 was
Figure 3 Growth hormone secretagogue receptor expression in canine mammary tumors. (A) Light micrographs of canine mammary
adenomas, adenocarcinomas of the 1st, the 2nd, the 3rd grade of malignancy and tumors that gave local/distal metastases (total n = 50) obtained
with Olympus BX60 microscope (at the magnification of x20). The growth hormone secretagogue receptor (GHS-R) antigen is represented by
brown colored precipitate in cytoplasm. (B) The graph of integrated optical density (IOD) of growth hormone secretagogue receptor
(GHS-R)-positive cells in canine mammary tumors. The colorimetric intensity of the IHC-stained antigen spots was evaluated by a
computer-assisted image analyzer (Olympus Microimage™ Image Analysis, software version 5.0 for windows, USA). Ten to 20 pictures in each
slide were analyzed. The result are presented as a mean (±SEM) from 10 tumors in each group. The statistical analysis was performed using Prism
version 5.00 software (GraphPad Software, California, USA). The one-way ANOVA and Tukey HSD post-hoc were applied to analyze the results.
p- < 0.01 was regarded as highly significant and marked as **.
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ghrelin (p < 0.05) compared to control cells (Figure 7A).
Ghrelin treatment at dose of 1 nM and 10 nM also
increased cell viability in the CMT-W1M cell line (14%Figure 4 Ghrelin and growth hormone secretagogue receptor expres
relative gene expression level (ratio) of (A) ghrelin and (B) growth hormon
(CMT-W1, CMT-W2) and their lung metastases (CMT-W1M and CMT-W2M) d
(±SEM). The statistical analysis was performed using Prism version 5.00 soft
post-hoc were applied to analyze the results. p < 0.05 was regarded as signabove control, p < 0.01 and 8% above control, p < 0.05; re-
spectively) (Figure 7B). The highest response for ghrelin
treatment was observed in the CMT-W2 cell line. The
viability of the CMT-W2 cells was significantly increasedsion at mRNA level in canine mammary carcinoma cell lines. The
e secretagogue receptor in canine mammary carcinoma cell lines
etermined using Real-time qPCR. The result are presented as a mean
ware (GraphPad Software, USA). The one-way ANOVA and Tukey HSD
ificant and marked as *.
Figure 5 Ghrelin expression in canine mammary carcinoma cell lines. (A) Representative pictures of canine mammary adenocarcinoma cell
lines (CMT-W1, CMT-W2) and their lung metastases (CMT-W1M and CMT-W2M). The majority of the cancer cells showed a strong cytoplasmic
staining reaction (brown color) of ghrelin (anti-pre proghrelin antibody obtained from Abcam, UK was used). Pictures were obtained with
Olympus BX60 microscope (at the magnification of x20). (B) The graph of integrated optical density (IOD) of the ghrelin-positive cells in
examined canine cancer cell lines. The colorimetric intensity of the IHC-stained antigen spots was evaluated by a computer-assisted image
analyzer (Olympus Microimage™ Image Analysis, software version 5.0 for windows, USA). Twenty pictures in each slide were analyzed. The results
are presented as a mean (±SEM) from tree separate experiments. The statistical analysis was performed using Prism version 5.00 software
(GraphPad Software,USA). The one-way ANOVA and unpaired t-test were applied. p < 0.01 was regarded as significant and marked as **.
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(p < 0.01), 10 nM (p < 0.01), 100 nM (p < 0.001) and
1000 nM (p < 0.01) by approximately 25%, 19%, 18% and
16%, respectively (Figure 7C). Metabolic activity of the
CMT-W2M cells was not significantly changed after in-
cubation with ghrelin (Figure 7D). The pre-treatment
of cells for 1 hr with specific inhibitor of GHS receptor
([D-Lys3]-GHRP6) completely abolished the cells re-
sponse for ghrelin (Figure 8) what confirmed that in
examined cell lines ghrelin acts via GHS-R.
The role of ghrelin on cellular proliferation was con-
firmed by BrdU incorporation assay. Ghrelin treatment
at 1 nM and 10 nM doses increased proliferation of can-
cer cells to 57.6 ± 0.8% and 55.9 ± 0.5% (p < 0.001) in
CMT-W1 cell line and to 62.5 ± 0.4% and 57.7 ± 1.8%
(p < 0.01) in CMT-W1M cell line (Figure 9A, B). Grelin
treatment at the concentration of 1 nM caused increase
of proliferation to 58.5 ± 0.6% (p < 0.01) in CMT-W2 cell
line, however treatment with specific GHS-R inhibitor at
200 μM dose induced anti-proliferative effect, which was
not observed in other examined cell lines (Figure 9C).
Cell proliferation was not affected by ghrelin in the
CMT-W2M cell line (Figure 9D).In both experiments it was impossible to create a
dose–response curve. The results indicated that smaller
doses of ghrelin (1-10 nM) significantly increased cancer
cells proliferation, however any dose-dependent effect
was not observed (regression analysis).
ghsr RNA interference
Based on the MTT assay results, the optimal cell num-
ber for transfection experiment was 100 000 per well on
96-well plate. Culture of 100 000 cells per well at the be-
ginning of the experiment ensured 60% confluence (due
to absorbance) at the day of transfection. Transfection
reagent toxicity evaluation revealed that in case of CMT-
W1 cell line the best viability results were reached using
Lipofectamine RNAiMAX (Invitrogen, USA). The high-
est viability of the cells (the same as in control cells, due
to absorbance) was reached with Lipofectamine RNAi-
MAX at the concentration of 0.8 μl per well.
The confocal microscopy observations and subsequent
computer-assisted image analysis (Olympus Microimage™
Image Analysis, software version 4.0 for Windows, USA)
revealed that Lipofectamine RNAiMAX at the concentra-
tion of 0.8 μl per 100 000 cells per well proved a highly
Figure 6 Growth hormone secretagogue receptor expression in canine mammary carcinoma cell lines. (A) Representative pictures of
canine mammary adenocarcinoma cell lines (CMT-W1, CMT-W2) and their lung metastases (CMT-W1M and CMT-W2M). Cancer cells showed a
cytoplasmic staining reaction (brown color) of growth hormone secretagogue receptor (anti-Growth Hormone Secretagogue Receptor antibody
obtained from Santa Cruz Biotechnology, USA was used). Pictures were obtained with Olympus BX60 microscope (at the magnification of x10).
(B) The graph of integrated optical density (IOD) of growth hormone secretagogue receptor (GHS-R)-positive cells in examined canine cancer cell
lines. The colorimetric intensity of the IHC-stained antygen spots was evaluated by a computer-assisted image analyzer (Olympus Microimage™
Image Analysis, software version 5.0 for windows, USA). Twenty pictures in each slide were analyzed. The results are presented as a mean (±SEM)
from tree separate experiments. The statistical analysis was performed using Prism version 5.00 software (GraphPad Software, USA). The one-way
ANOVA and unpaired t-test were applied. p < 0.05 was regarded as significant and marked as *.
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ficiency at the level of 90%. Consequently, experiments
were conducted under the same conditions.
The control cells used for further experiments were
cultured under the transfection conditions with tranfec-
tion reagent + non-coding RNA.
The real-time qPCR and immunohistochemistry re-
sults confirmed the effect of ghsr gene silencing. The
lowest expression of ghsr (45.07% reduction in expres-
sion (when compared against control cells) was found in
the cells treated with the mixture of ghsr1 and ghsr2
sequences (p < 0.001). Only about 15-28% reduction of
ghsr expression, comparing against the control cells, was
observed in case of ghsr1 sequence given at two concen-
trations (p < 0.05). We observed 27.51% and 48.69% re-
duction of expression compared to control cells after the
ghsr2 and ghsr20 interference, respectively (p < 0.05 and
p < 0.01, respectively).
The immunohistochemical studies revealed higher ef-
ficacy of gene silencing at the protein level than at the
mRNA level. The most effective was ghsr1 sequence
causing 84.41% reduction in protein levels compared
against the control cells. Ghrs10 sequence caused 68.72%of protein expression reduction, whereas ghsr2 sequence
caused 56.17% reduction. Ghsr20 and mixture of ghsr1
and ghsr2 sequences caused 60.47% and 60.75% reduc-
tion of protein expression. All these results have been
statistically significant at the level of p < 0.05. For apop-
tosis analysis the ghsr1 siRNA duplex was used.
Ghrelin is an anti-apoptotic factor in canine carcinoma
cell lines
For analysis of ghrelin influence on apoptosis, the
Annexin V and PI double staining was applied. The num-
ber of apoptotic cells represented as a percentages of
Annexin-V-positive cells was significantly decreased after
the ghrelin treatment at the dose of 1 nM (decreased
from 11.9 to 7.7%) in the CMT-W1 cell line (p < 0.001)
and in the CMT-W2 cell line (p < 0.05) (decreased from
17.2% to 13.5%) (Figure 10A, C). Anti-apoptotic effect of
ghrelin was higher in the cell lines isolated from lung
metastases of mammary cancer. In control conditions
9.7% and 11.6% of cells has been identified as apoptotic
in CMT-W1M and CMT-W2M cell line, respectively.
After ghrelin treatment at the concentration of 1 nM and
10 nM the number of apoptotic cells decreased to 4%
Figure 7 Ghrelin affects viability of canine mammary carcinoma cells. The canine mammary cancer cells viability determined by MTT assay
in control conditions (ctrl) and in a presence of n-octanoylated ghrelin peptide (Peptides International) at concentrations of 1, 10, 100 and 1000
nM for 24 h. Absorbance at 570 nm has been converted to percentages above control (±SEM). The experiment has been conducted in n = 15
repetitions. Ghrelin treatment at the concentration of 1 and 10 nM; 1 and 100 nM, 1-1000 nM significantly increased cell viability of the
CMT-W1 (A), CMT-W1M (B) and CMT-W2 (C) cell lines, respectively. No significant differences has been observed in CMT-W2M cell line (D). The
statistical analysis was performed using Prism version 5.00 software (GraphPad Software, USA). One-way ANOVA followed by Dunnett’s post hoc
comparisons were applied. p < 0.05 was marked as *, p < 0.01 was marked as ** and p < 0.001 was marked as ***.
Figure 8 Canine mammary carcinoma cells response for ghrelin was completely abolished after pre-treatment with specific inhibitor of
GHS receptor ([D-Lys3]-GHRP6). The canine mammary cancer cells viability determined by MTT assay in control conditions (CTR) and in one
hour pre-incubation with specific inhibitor of GHS receptor ([D-Lys3]-GHRP6) at concentrations of 100 and 200 μM and following incubation with
n-octanoylated ghrelin peptide (10 nM) (Peptides International) for 24 hrs. Absorbance at 570 nm has been converted to percentages (±SEM). The
experiment has been conducted in n = 15 repetitions. The pre-treatment with specific inhibitor of GHS receptor completely abolished the cells
response for ghrelin treatment (10 nM) in the CMT-W1 (A), CMT-W1M (B) and CMT-W2 (C) cell lines, respectively. The statistical analysis was
performed using Prism version 5.00 software (GraphPad Software, USA). One-way ANOVA followed by Dunnett’s post hoc comparisons were
applied. No significant differences has been observed.
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Figure 9 Ghrelin stimulates proliferation of canine mammary carcinoma cells. The effect of n-octanoylated ghrelin peptide (Peptides
International) and GHS-R-specific peptide antagonist [D-Lys3]-GHRP6 (Peptides International) treatment on proliferation of canine mammary
cancer cells assessed by BrdU incorporation test (BD Bioscience, USA). The number of proliferating cells represented as a percentage of
BrdU-positive cells (±SD) obtained with FACS Aria II (Becton Dickinson) is significantly increases after the ghrelin treatment at concentration of
1 and 10nM in CMT-W1 (A), and CMT-W1M (B) cell line whereas at concentration of 1 nM dose in CMT-W2 (C). In this cell line a decrease in
number of proliferating cells after ghrelin receptor inhibitor treatment (200μM) has been observed. No significant differences has been observed
in CMT-W2M cell line (D) nor after the ghrelin treatment, neither after the ghrelin receptor inhibitor treatment. The experiment has been
conducted in three repetitions. The statistical analysis was performed using Prism version 5.00 software (GraphPad Software, USA). One-way
ANOVA followed by Tukey HSD post-hoc test were applied. p < 0.05 was marked as *, p < 0.01 was marked as ** and p < 0.001 was marked as ***.
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5.6% and 5,4% (respectively) in the CMT-W2M cell line.
The statistical analysis showed that differences were
highly significant (p < 0.001) (Figure 10B, D). Among all
of the examined cell lines only in CMT-W1M cell line in-
cubation with 200 μM GHS-R-specific peptide inhibitor
([D-Lys3]-GHRP6) for 24hrs significantly increased the
number of apoptotic cells (17.3%, p < 0.001) (Figure 10B,
E). In order to investigate if this effect was caused by tox-
icity of this peptide, we knocked-down the ghsr expres-
sion by RNAi to confirm the functional importance of
the GHS-R in apoptosis in CMT-W1M cell line. Our re-
sults showed that siRNA treatment significantly increased
number of early apoptotic cells in CMT-W1M cell line(p < 0.05) up to 1.7% (Figure 11A). Cancer cells treat-
ment with GHS-R inhibitor increased number of early
apoptotic cells highly significantly (p < 0.01) up to 2.6%
(Figure 11B). These differences may be caused by not
completely knock-down of GHSR expression (about 15%
of cells remained untransfected).
Ghrelin promotes migration and invasion of canine
mammary carcinoma cells
The wound healing assay showed that ghrelin treatment
at the concentration of 100 nM increased migratory abil-
ities of the CMT-W1, CMT-W1M and CMT-W2 cell
lines (Figure 12A, B, C, D), however, no effect on CMT-
W2M cells has been observed (Figure 12E). CMT-W1
Figure 10 Ghrelin inhibits basal apoptosis of canine mammary carcinoma cells. The effect of n-octanoylated ghrelin peptide (Peptides
International) and GHS-R-specific peptide antagonist [D-Lys3]-GHRP6 (Peptides International) treatment on apoptosis of CMT-W1 (A), CMT-W1M
(B), CMT-W2 (C) and CMT-W2M (D) cell lines, assessed by the Annexin V/PI test (BD Bioscience, USA). The number of apoptotic cells represented
as a percentages of Annexin-V-positive cells (±SD) obtained with FACS Aria II (Becton Dickinson) is significantly decreased after the 1nM ghrelin
treatment in CMT-W1, and CMT-W2 cell lines and after 1 nM and 10 nM ghrelin treatment in CMT-W1M, and CMT-W2M cell lines. The
administration of ghrelin receptor inhibitor ([D-Lys3]-GHRP6) at concentration of 200 μM significantly increased the number of apoptotic cells in
the CMT-W1M cell line. The experiment has been conducted in three replicates. p < 0.05 was marked as *, p < 0.01 was marked as ** and
p< 0.001 was marked as ***. One-way ANOVA followed by Tukey HSD post-hoc test were applied. (E) The representative histograms and
cytograms of CMT-W1M cell line double stainined with AnnexinV-FITC and propidium iodide (PI). Cells located on the right side of the histograms
represented apoptotic cells. On the cytograms are showed normal, early apoptotic, late apoptotic and necrotic cells. Left bottom quadrant shows
normal cells, top left quadrant shows necrotic cells (stained with PI only; damaged cell membrane but no phosphatydilserine exposure), right
bottom quadrant shows the early apoptotic cells (stained with Annexin V only; intact cell membrane) and top right quadrant shows cells in late
stage of apoptosis (stained with Annexin V and PI - phosphatydilserine exposure and damaged cell membrane).
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closed the wound (93 ± 2.7%) in 9 hours after scratching,
whereas CMT-W1 control cells after 9 hrs closed only
60.9 ± 1.4% of the wound (Figure 12A). Similarly, CMT-
W1M cells incubated with ghrelin (100 nM) closed the
wound at the level of 86.9 ± 6.6% in 9 hours after scratch-
ing, whereas CMT-W1M control cells after 9 hrs closed
only 65.6 ± 9.4% of the wound (Figure 12B). Also, CMT-
W2 cells incubated with ghrelin (100 nM) closed the
wound at the level of 73.6 ± 6.2% in 9 hours after scratch-
ing, whereas CMT-W2 control cells after 9 hrs closed
only 59.4 ± 2.9% of the wound (Figure 12D). Administra-
tion of GHS-R-specific peptide inhibitor ([D-Lys3]-GHRP6)at 100 μM dose decreased the motility of the CMT-W1
cells, whereas had no effect on motility of the CMT-W1M
or CMT-W2 cells even at the concentration of 1000 μM.
CMT-W1 cells incubated with ghrelin receptor inhibi-
tor (100 μM) closed 44,7 ± 2.0% and 83,8 ± 5.3% of the
wound in 9 and 24 hrs after scratching (respectively)
(Figure 12A, C). CMT-W2M control cells and ghrelin
(100 nM) treated cells closed 60,2 ± 6,8% and 70,3 ± 3,6%
of the wound (respectively) in 9 hours after scratching,
however the difference was not statistically significant
(Figure 12E). CMT-W2M completely (100%) closed the
wound after 24 hours after scratching in control condi-
tions and after ghrelin treatment. GHS-R-specific peptide
Figure 11 The impact of siRNA and GHS-R-specific peptide antagonist on early apoptosis of canine mammary carcinoma cells. (A) The
effect of knock-down of growth hormone secretagogue receptor by siRNA and (B) GHS-R-specific peptide antagonist [D-Lys3]-GHRP6 (Peptides
International) (1000 μM) on early apoptosis of CMT-W1M cell line assessed by the Annexin V/PI test (BD Bioscience, USA). The number of early
apoptotic cells represented as a percentages of Annexin V stained cells (±SD) with intact cell membrane obtained with FACS Aria II (Becton
Dickinson) highly significantly increased after a ghrelin inhibitor treatment (p < 0.01 marked as **) and significantly increased after siRNA
treatment (p < 0.05 marked as *). The experiment has been conducted in three replicates. The statistical analysis was performed using Prism
version 5.00 software (GraphPad Software, USA). One-way ANOVA followed by Tukey HSD post-hoc test and t-test were applied.
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ity of those cells (Figure 12E).
Cell migration assessed in Boyden chambers was in-
creased by incubation with 10 nM of ghrelin in CMT-W1
cell line and in the other cell lines (CMT-W1, CMT-W2,
CMT-W2M) by incubation with 1 and 10 nM of ghrelin
(Figure 13A).
Cancer cell invasion was increased by ghrelin treat-
ment for 24 hours. Ghrelin was the most effective at the
10 nM concentration in CMT-W1, CMT-W1M, CMT-
W2M, whereas it was the most effective in CMT-W2
cell line at 1 nM concentration (Figure 14A). The ana-
lysis conducted using Olympus microscopy BX60 con-
firmed the results (Figures 13 and 14B).Discussion
The co-expression of ghrelin and GHS-R has previ-
ously been observed in various neoplasms and related
cancer cell lines in humans (for review see: [10]). It
may suggest their role in neoplastic cell growth and
development through autocrine/paracrine mechanism.
However, as far as we realize, there are no published
reports regarding similar data on tumors in domestic
animals. This is the first report of ghrelin and its re-
ceptor expression in canine mammary tumor tissues and
cell lines isolated from the canine primary carcinomas(CMT-W1 and CMT-W2) and from their lung metasta-
ses (CMT-W1M and CMT-W2M).
We have demonstrated the expression of ghrelin in be-
nign and malignant canine mammary tumors (Figures 1,
2, 3) and in all of the examined cancer cell lines (Figures 4,
5, 6). Interestingly, we observed significantly higher ex-
pression of ghrelin in the distant metastases than in the
primary carcinomas, which suggest that ghrelin might be
involved in mechanism of metastasis (Figure 2). A recent
study on human colorectal cancers indicated that ghrelin
might initiate malignant transformation and might con-
tribute to the cancer spread [33]. It was also hypothesized
that ghrelin mediates the physiological responses of tissues
which surround the tumor, to malignant changes [34].
The presence of GHS-R mRNA has been previously
detected in all of the examined canine cancer cell lines
[23]. Similarly to mRNA expression patterns, GHS-R
protein showed significantly higher expression in cell
lines isolated from lung metastases of mammary can-
cer (CMT-W1M and CMT-W2M) what may indicate its
role in metastasis (Figures 4, 6). Moreover, we have dem-
onstrated that expression of ghrelin receptor varies in
canine mammary tumors depending on the histological
grade of malignancy (Figure 3). The GHS-R expression
level was higher in well or moderately differentiated
cancers of the 1st and the 2nd grade of malignancy com-
pared to poorly-differentiated cancers of the 3rd grade of
Figure 12 Wound healing assay of canine mammary carcinoma cells after ghrelin treatment. Quantification of migration of CMT-W1 (A),
CMT-W1M (B) CMT-W2 (D), CMT-W2M (E) cell lines represented as percentages of scratch closure and calculated as follows: % of scratch
closure = a-b/a, where (a) is a distance between edges of the wound, and (b) is the distance which remained cell-free during cell migration to
close the scratch. Ghrelin treatment at the concentration of 100nM increased cells motility after 9 and 24 hrs in the CMT-W1, CMT-W1M and
CMT-W2 cell lines. Administration of ghrelin receptor inhibitor (100μM) decreased the motility of the CMT-W1 cells, whereas had no effect on
motility of the cells of remaining cell lines. Photographs of cells invading the scratch were taken at the starting point and after 3, 6, 9, and 24 hrs
using phase contrast microscopy (IX 70 Olympus Optical Co., Germany). (C) Representative pictures of scratch closure in control conditions, after
ghrelin treatment (100nM) and GHS-R-specific peptide inhibitor [D-Lys3]-GHRP6 (100 μM) treatment in CMT-W1 cell line obtained using Olympus
BX60 microscope (x4). Pictures have been analyzed using a computer-assisted image analyzer (Olympus Microimage™ Image Analysis, software
version 5.0 for Windows, USA). The experiment has been conducted three times. Two-way ANOVA and Bonferroni post-hoc tests were applied.
p < 0.05 was marked as *, p < 0.01 was marked as ** and p < 0.001 was marked as ***.
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reported previously, that expression and functionality of
specific binding sites for GHS (growth hormone secreat-
gogues) in various types of breast and thyroid carcinomas
was maintained in better-differentiated tumors and was
decreased in less-differentiated neoplasms [11,12]. Simi-
lar expression patterns of GHS-R were observed in hu-
man gastric and colorectal cancers [33,34], where theGHS-R expression level was lowest in undifferentiated
tumors and correlated inversely with histological grade
of malignancy and TNM stage. Moreover, patients with
more weight loss showed lower expression of GHS re-
ceptor [34]. Therefore, decreased ghrelin receptor ex-
pression seemed to correlate with poor prognostic
factors such as poor differentiation, advanced stage and
malnutrition.
Figure 13 Ghrelin promotes migration of canine mammary carcinoma cells. (A) Quantification of migration of examined cell lines
(CMT-W1, CMT-W1M, CMT-W2, CMT-W2M) represented as relative florescent units obtained by florescent plate reader Infinite 200 PRO Tecan™
(Ex. 485, Em. 530). Ghrelin treatment for 24 hrs at the concentration of 1 nM and 10 nM increased cancer cells migration through membrane of
Boyden chamber assay in CMT-W1M, CMT-W2, CMT-W2M cell lines. In CMT-W1 cell line only grelin concentration of 10 nM was effective. The
experiment has been conducted three times. The statistical analysis was performed using Prism version 5.00 software (GraphPad Software, USA).
One-way ANOVA followed by Tukey HSD post-hoc test and unpaired t-test were applied. p < 0.05 was marked as *, p < 0.01 was marked as **.
(B) Fluorescence microscopic analysis of the migrated CMT-W2 cells using Olympus microscopy BX60 at x4 magnification.
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ghrelin in cancer cell biology. Our results revealed that
ghrelin stimulates canine mammary cancer cells prolif-
eration and inhibits apoptosis, possibly via an autocine/
paracrine mechanism. Although the role of ghrelin in
cancer cells was investigated in multiple experiments
using human and rat cancer cell lines, the results were
equivocal. Some investigators have found ghrelin as an-
tiproliferative factor [11-14,19], but other have found it
a growth stimulator of cancer cells [15-18,20-22]. Cassoni
and co-workers described an inhibition of cell prolif-
eration in human thyroid, breast and lung cancer by
ghrelin [11,12,14]. Authors found that ghrelin given for
24 hrs at relatively high doses (100 or 1000 nM) de-
creased cell proliferation. However, after incubation of
these cells with ghrelin for 96 hrs, the effect was abol-
ished [11]. Volante et al. [19] have confirmed antiprolifer-
ative effect of ghrelin in thyroid cancer cells showing
significant growth reduction after 48 hrs and 96 hrs
of incubation with ghrelin at the concentration of100-1000 nM. Interestingly, Cassoni et al. [13] have
showed dose-dependent effect of ghrelin treatment in
prostate cancer cells. Contrary to the mentioned reports
the pro-proliferative effect of ghrelin in several human
cancer cell lines has also been well documented. Ghrelin
at doses ranging from 1 to 10 nM, which encompasses
normal circulating ghrelin levels increased cellular prolif-
eration after 72 h of incubation in breast and prostate
cancers [15,16,21]. Ghrelin treatment significantly sti-
mulated cells growth in the highly metastatic (MDA-
MB-435) breast cancer cell line up to 36% above control.
The most significant proliferative response to ghrelin
treatment occurred at the concentrations of 10 and 100
nM in the MDA-MB-231 cell line, and 1–10 nM in the
MDA-MB-435 cell line [16]. Thus, these results show
that ghrelin given in high doses inhibits cancer cell pro-
liferation, whereas given at low doses increases prolifera-
tion. Our results also indicated that ghrelin given at the
dose of 1 or 10 nM increased canine mammary cancer cells
proliferation in three of four examined cell lines (Figure 7,
Figure 14 Ghrelin promotes invasion of canine mammary carcinoma cells. (A) Quantification of invasion of examined cell lines
(CMT-W1, CMT-W1M, CMT-W2, CMT-W2M) represented as relative florescent units obtained by florescent plate reader Infinite 200 PRO Tecan™
(Ex. 485, Em.530). Ghrelin treatment for 24 hrs at the concentration of 1 nM in CMT-W2 cell line and of 10 nM in remaining cell lines increased
cancer cells invasion through membrane of Boyden chamber system pre-coated by BD Matrigel™ Matrix. The experiment has been conducted
three times. The statistical analysis was performed using Prism version 5.00 software (GraphPad Software, USA). One-way ANOVA followed by
Tukey HSD post-hoc test and unpaired t-test were applied. p < 0.05 was marked as *, p < 0.01 was marked as **. (B) Fluorescence microscopic
analysis of the invaded through Matrigel layer CMTW-2 cancer cells using Olympus microscopy BX60 at x4 magnification.
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also in three of four examined cell lines. In one cell line,
ghrelin did not cause any affect.
To clarify the role of ghrelin in cell proliferation the
cell cycle analysis was conducted [22]. This study re-
vealed that although ghrelin did not change the pro-
portion of cells in the G0/G1, S or G2/M phases of cell
cycle, it caused a decrease in the number of apoptotic
cells in sub-G0 phase. In fact ghrelin was reported to be
the antiapoptotic factor in colonic cancer cells [35] as
well as in many other types of cells like adipocytes [36],
osteoblastic cells [37], or human endothelial cells [38].
The antiapoptotic activity of ghrelin is also supported
by our findings (Figure 10). We have showed that ghre-
lin decreases the number of apoptotic cells in all of the
examined canine mammary cancer cell lines (in all of the
examined cell lines ghrelin treatment at a dose of 1 nM
significantly decreased apoptosis, whereas in two cell
lines incubation of cells with the ghrelin concentration of10 nM also decreased the number of apoptotic cells). Be-
cause in CMT-W1M cell line we observed a significant
increase in number of apoptotic cells after the treatment
with ghrelin inhibitor, our next step was to knock-down
the ghsr gene to check if the toxic effect was caused by
the inhibitor itself or by blocking the GHS-R. Our results
showed that treatment of CMT-W1M cell line with ghsr-
specific siRNA also increased the number of apoptotic
cells (early apoptotic) (Figure 11). An increase in number
of apoptotic cells was slight, however significant, which
can be explained by efficacy of gene silencing. In our ex-
periment only 85% of cells remained transfected.
Recently, a few studies have focused on the involve-
ment of ghrelin in cancer cells motility and ability to
metastasis. Duxbury and co-workers [18] investigated
the role of ghrelin in metastatic potential of poorly dif-
ferentiated human pancreatic cancer cells. They found
that ghrelin at 10 nM concentration increased not only
the proliferation rate of cancer cells but also cellular
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study showed the promotion of proliferation and inva-
siveness of human colorectal cancer cells by ghrelin in
an autocrine and paracrine manner. This effect was al-
most completely abolished when the cells were pre-
treated with either GHS-R antagonist (D-[Lys3]GHRP6)
or a neutralizing ghrelin – specific antibody [33]. Fur-
thermore Dixit et al. [39] revealed that ghrelin acting via
functional GHS-R1a caused increase in intracellular cal-
cium mobilization and led to actin polymerization and
membrane ruffling, which resulted in an increase of mi-
gration and invasion of carcinoma cells.
Our study also showed a role of ghrelin in cancer cells
migration and invasion. We have demonstrated that
ghrelin given at the concentration of 100 nM increased
the migration ability of canine carcinoma cell lines
CMT-W1 and CMT-W1M, evaluated by wound healing
test (Figure 12). Moreover ghrelin given at the concen-
tration of 1 and/or 10 nM significantly increased migra-
tion and invasion of all the examined canine carcinoma
cell lines (Figure 13, Figure 14).
The fact that the examined carcinoma cell lines re-
spond in different manner to the various ghrelin doses
may be related with differences in endogenous ghrelin
production levels. Differences between effective ghrelin
doses that stimulate cells proliferation or survival and
doses that increase cells migration can be explained by
the fact that these different cellular activities are me-
diated by different cellular pathways. Literature data
show that ghrelin increases cellular migration acting on
CaMKII, AMPK, and NF-kB pathways [40], whereas
increases cellular proliferation and survival acting on
ERK1/2 [20]. Thus, probably various ghrelin doses are
required to activate various cellular pathways.
Conclusion
We have showed that ghrelin and GHS-R are differen-
tially expressed in canine mammary tumors. The lowest
expression of GHS-R in tumors of the 3rd grade of ma-
lignancy may by a potential prognostic factor. Taken to-
gether, the data demonstrated that exposure to low doses
of ghrelin stimulate cellular proliferation, inhibit apoptosis
and promote motility and invasion of canine mammary
carcinoma cells. However, further studies are required to
investigate the molecular mechanism responsible for
ghrelin action in cancer cells. Our study indicates that
inhibition of ghrelin/GHS-R axis may be a potential thera-
peutic target of mammary cancers in dogs in the future.
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